TIDMEVG

RNS Number : 0864N

Evgen Pharma PLC

15 May 2020

Evgen Pharma plc

("Evgen" or the "Company")

Share price movement

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, notes the increase in the Company's share price in recent days.

Evgen can confirm that it is in discussions with a potential source of funds that would help pay for a clinical trial in Covid-19 patients, with Evgen providing SFX-01 in support of such a trial.

A further announcement will be made if these discussions are successful.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                           via Walbrook 
 Barry Clare, Chairman 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                           +44 (0)20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane / Manasa Patil (ECM) 
 
 Walbrook PR                              +44 (0)20 7933 87870 or evgen@walbrookpr.com 
                                                     +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                    741 001

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases . The Company's core technology is Sulforadex (R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

SPMAAMBTMTTBBBM

(END) Dow Jones Newswires

May 15, 2020 07:30 ET (11:30 GMT)

Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Evgen Pharma Charts.
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Evgen Pharma Charts.